PDCD1 and neoplasm: In a prospective cohort study of 73 NSCLC patients treated with anti-PD-1 antibodies, 34.2% of patients developed cutaneous irAEs, and TCR chronotyping of samples from four patients with matched skin and tumor biopsies revealed the presence of a T-cell clone shared between the skin and tumor in all patients [30].